[Treatment of lepromatous leprosy by ethionamide].
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D001361:Avitaminosis / Q000139:chemically induced; D002648:Child; D005000:Ethionamide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007918:Leprosy / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D008105:Liver Cirrhosis, Biliary / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009166:Mycobacterium leprae / Q000302:isolation & purification; D009536:Niacinamide / Q000037:antagonists & inhibitors; D011605:Psychoses, Substance-Induced / Q000209:etiology
D009536:Niacinamide; D005000:Ethionamide
Traitement de la lèpre lépromateuse par l'ethionamide.